Curriculum Vitae

NAME: Janina Baranowska-Kortylewicz

ADDRESS: Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986125 Nebraska Medical Center
Omaha, NE 68198-6125
telephone: 402-559-8906
e-mail: jbaranow@unmc.edu

EDUCATION

1985	Ph.D. Chemistry; Department of Chemistry, University of Kentucky, Lexington, Kentucky; Dissertation title: *Platinum(II) Interactions with Nucleobase Derivatives: Potential Anticancer Complexes.* (Walter T. Smith, Jr., Ph.D., Advisor)
1977	M.Sc. Organic Synthesis and Technology; Department of Chemistry, Wrocław University of Science and Technology (Politechnika Wrocławska), Poland. Thesis title: *Synthesis and Characterization of p-Aminobenzaldehyde-Based Herbicides.* (Stanisław Witek, Ph.D., Advisor)
1980 - 1985	Graduate School, Ph.D. candidate; Department of Chemistry, University of Kentucky, Lexington, Kentucky
1978 - 1979	Ph.D. Graduate Student; Department of Chemistry, Wrocław University of Technology, (Politechnika Wrocławska), Poland
1973 - 1977	M.Sc. Graduate Student; Department of Chemistry, Wrocław University of Technology, (Politechnika Wrocławska), Poland

POST-DEGREE EDUCATION AND TRAINING

June 1986 - July 1987	National Institutes of Health Research Fellow; NIH Radiation Biology Training Program 5T32CA09078-11 (John B. Little, PhD, PI; S. James Adelstein, MD, PhD, Mentor), Department of Radiology, Harvard School of Public Health and Harvard Medical School, Boston, Massachusetts
June 1985 - June 1986	Research Associate in Chemistry, Albert B. Chandler Medical Center, Department of Obstetrics and Gynecology (Edward J. Pavlik, PhD and Kathy Nelson, PhD, Mentors), University of Kentucky, Lexington, Kentucky
Oct. 1977 - Sept. 1979	Research Fellow; Institute of Organic Synthesis (Stanisław Witek, PhD, Advisor), Technology and Polymers, Wrocław University of Technology, Wrocław, Poland

CONTINUING EDUCATION AND TRAINING (past three years)

completed	valid to	
06/20/2022	06/19/2025	Collaborative Institutional Training Initiative Good Clinical Practice
06/20/2022	06/19-2025	Collaborative Institutional Training Initiative Biomedical Research
05/25/2022	05/24/2023	Mark I irradiator operator training
10/04/2021	10/04/2023	Title IX Employee Training
10/04/2021	10/03/2022	Fundamentals of FERPA
10/04/2021	10/03/2022	Information Security Awareness
10/04/2021	10/03/2022	Statement of Understanding
10/04/2021	10/03/2022	HIPAA 2021 Renewal

10/04/2021	10/03/2022	Safety and Emergency Preparedness
10/04/2021	10/04/2025	Conflict of Interest Training
10/04/2021	10/04/2023	Title IX & Reporting Sexual Misconduct
10/04/2021	10/03/2022	Bloodborne Pathogens
10/04/2021	10/04/2023	Inclusive Excellence: Excellence through Bridging Cultural Differences
09/16/2021	indefinitely	Employee COVID Commitment
09/03/2021	04/30/2024	Animal Contact Safety
12/12/2021	12/12/2022	Radiation worker safety training
03/14/2019	indefinitely	Pathways for Innovation
01/10/2019	indefinitely	Technology in Education in a Digital Age
01/10/2019	indefinitely	iWall
01/10/2019	indefinitely	Personalized Learning in Graduate Education
01/15/2019	indefinitely	Standards of Conduct Regarding Alcohol and Drugs

PROFESSIONAL EXPERIENCE

09/2020 – present	Research Professor, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska
09/2019 – 09/2020	Adjunct Research Professor, Volunteer, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska
08/2019 - 07/2005	Professor, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska
Present - 07/2005	Courtesy Professor, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska
Present - 07/2005	Courtesy Professor, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
09/2019 - 07/2001	Director, Radiolabeling Facility, University of Nebraska Medical Center, Omaha, Nebraska
09/2019 - 05/1995	Graduate College Faculty Fellow, University of Nebraska, Omaha, Nebraska
09/2019 – 03/1995	Graduate Faculty Member, University of Nebraska Medical Center, Omaha, Nebraska
Present - 2013	Current Member and Founding Member, Pediatric Cancer Research Group
09/2019 - Jan 2015	Member of Fred & Pamela Buffett Cancer Center Molecular Biochemical Etiology Program
01/2015 – 01/1995	Associate Member, Eppley Cancer Center, Omaha, Nebraska
06/2005 – 07/1998	Associate Professor, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska
06/2005 – 09/1999	Courtesy Associate Professor, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska
06/2005 – 07/1998	Courtesy Associate Professor, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
01/2003 – 01/1993	Faculty Member, UNMC Radiation Health Center, Omaha, Nebraska
07/1994 – 07/1999	Assistant Professor, Contributed Service Faculty, Department of Radiology, Creighton University School of Medicine, Omaha, Nebraska
07/1995 – 06/1998	Assistant Professor, Department of Radiation Oncology, UNMC, Omaha, Nebraska

01/1993 – 06/1998	Courtesy Assistant Professor, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
07/1994 – 07/1995	Courtesy Assistant Professor, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska
01/1993 – 07/1995	Assistant Professor, Department of Radiology, UNMC, Omaha, Nebraska
07/1989 – 01/1993	Instructor in Radiology, Department of Radiology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts
07/1989 – 01/1993	Chief Chemist, Nuclear Medicine Division, Department of Radiology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts
07/1987 – 07/1989	Research Associate in Radiology; Department of Radiology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts
05/1982 – 09/1982	Research Assistant; Institute of Mining and Minerals Research, University of Kentucky, Lexington, Kentucky
08/1981 – 09/1981	Research Assistant; Department of Biochemistry, Center on Aging, University of Kentucky, Lexington, Kentucky
09/1980 – 06/1985	Teaching Assistant; Department of Chemistry, University of Kentucky, Lexington, Kentucky

HONORS AND AWARDS

2022 Research Innovation Awards for New Invention and U.S. Patent; UNeMed and UNMC Vice Chancellor for Research

2017 Outstanding Reviewer for International Journal of Radiation Oncology, Biology, Physics. July 2017

2016 Research Innovation Awards for New Inventions, UNeMeD and UNMC Vice Chancellor for Research

2016 Award for the Creator of Licensed Technology, UNeMed, Omaha, NE

2016 Recognition for Inventors with Issued Patents, UNeMed, Omaha, NE

2014 Distinguished Graduate of the Wrocław University of Science and Technology Award (Wyróżniony Absolwent Politechniki Wrocławskiej) https://absolwent.pwr.edu.pl/odznaka-wyroznionego-absolwenta-2014/

2014 Research Innovation Award for New Inventions, UNeMed and the UNMC Vice Chancellor for Research

2013 Certificate of Appreciation for Valuable Contribution, American Chemical Society, USA

2011 Research Innovation Award for New Inventions, UNeMed and the UNMC Vice Chancellor for Research

2009 Research Innovation Award for New Inventions, UNeMed and the UNMC Vice Chancellor for Research

2009 UNMC Chancellor's Council Silver "U" Award, Two Time Recipient, University of Nebraska Medical Center, Omaha, Nebraska

2008 Most Promising New Invention Award from the UNMC Vice Chancellor for Research and UNeMed

2004 Thank "U" Award from Dr. Charles A. Enke, Chairman, Department of Radiation Oncology to recognize a special achievement; University of Nebraska Medical Center, Omaha, Nebraska

2004 Annual Outstanding Performance Stipend, University of Nebraska Medical Center, Omaha, Nebraska

2003	Degree of Appreciation in recognition of contribution and continuing commitment to UNMC College of Medicine bestowed by Harold M. Maurer, Chancellor and James O. Armitage, Dean
2002	Annual Outstanding Performance Stipend, University of Nebraska Medical Center, Omaha, Nebraska
2001	Annual Outstanding Performance Stipend, University of Nebraska Medical Center, Omaha, Nebraska
1999	Annual Outstanding Performance Stipend, University of Nebraska Medical Center, Omaha, Nebraska
1999	UNMC Chancellor's Council Silver "U" Award, University of Nebraska Medical Center, Omaha, Nebraska
1998	Honorable mention, McGoogan Library of Medicine Art Show, photography
1998	UNMC Recognition of Service for Five Years of Dedicated Service, University of Nebraska Medical Center, Omaha, Nebraska
1997	UNMC Chancellor's Special Professional Achievement Award, Omaha, Nebraska
1984	Award of Merit for Outstanding Teaching Assistants; University of Kentucky, Lexington, Kentucky
1983	Vice-President of the Association of Graduate Students, University of Kentucky, Lexington, Kentucky

MEMBERSHIPS IN SCIENTIFIC ORGANIZATIONS

Present - 1981	Member, American Chemical Society, ACS
Present - 1987	Member, New York Academy of Sciences, NYAS
Present - 1990	Member, American Association for the Advancement of Science, AAAS
Present - 1991	Sustaining Member, Sigma Xi The Scientific Research Honor Society, Sigma Xi
Present - 1993	Member, Society of Nuclear Medicine and Molecular Imaging, SNMMI
Present - 2000	Member, International Society for Nucleosides, Nucleotides and Nucleic Acids, IS3NA
Present - 2017	Member, Great Plains IDeA-Clinical & Translational Research
1996 - 2012	Member, International Association of Radiopharmacology, IAR

REVIEWS, BOARDS, COMMITTEES AND COMMUNITY SERVICE

GRANT REVIEWER

2021	Chair of the NCI Special Emphasis Panel ZCA1 RPRB-H (J1) NCI Program Project III, https://public.era.nih.gov/pubroster/preSepIndex.era?AGENDA=432316&CID=100456.
2021	Member of the review panel for the NCI Clinical and Translational R21, Omnibus R03, and Co-Clinical Imaging Research Resources U24 Review (02/18/2021 -02/19/2021); https://public.era.nih.gov/pubroster/preSepIndex.era?AGENDA=412275&CID=100456
2021	Member of the review panel for ZRG1 OTC-A (80) SEP: NIH Research Enhancement Award (R15) in Oncological Sciences (05/26/2021); https://public.era.nih.gov/pubroster/preRosIndex.era?CID=101323&AGENDA=417973
2020	Member of the NCI Special Emphasis Panel ZCA1 SRB-X J2 P for NCI Clinical and Translational R21 and Omnibus R03 Review. October meeting.
2020	Member of the NCI Omnibus Review Committee for the Clinical and Translational R21 and Omnibus R03 (PAR-18-020, PAR-18-021) and Quantitative Imaging Tools and Methods (PAR18-248). January meeting.
2019	Member of National Cancer Institute SPORE II (P50) Review Committee ZCA1 RPRB-7
2018	Grant reviewer for National Cancer Institute Clinical and Translational Exploratory/Developmental Studies

2018	Member of National Cancer Institute Technology Panel: Drugs to Exploit the Immune Response Generated by Radiation Therapy
2018	Member of National Cancer Institute Technology Panel: Diagnostic Imaging for Cancer Immunotherapies
2017	Grant reviewer for NCI Clinical and Translational Exploratory/Developmental Studies
2016	Grant reviewer for the NIH CSR Clinical Molecular Imaging and Probe Development (CMIP)
2015	Grant reviewer for the NIH Oncological Sciences F09B fellowship
2012	Grant reviewer for the NIH CSR Clinical Molecular Imaging and Probe Development (CMIP)
2011	Chair for the CDMRP Prostate Cancer Research Program Physical Imaging 1 study section
2011	Grant reviewer for the NIH CSR Clinical Molecular Imaging and Probe Development (CMIP)
2011	Vice Chair and grant reviewer for the NIH CSR Recurring Special Emphasis Panel - Surgical Sciences, Biomedical Imaging, and Bioengineering IRG (SBIB-A55)
2010	Scientists reviewer for Prostate Cancer Research Program for the Department of Defense Congressionally Directed Medical Research Programs
2010 - 2006	Chartered member of NIH CSR Medical Imaging Study Section (MEDI)
2010 - 2006	Chartered member of NIH CSR Clinical Molecular Imaging Study Section, (CMI, MEDI-A)
2010	Vice Chair of NIH CSR Medical Imaging Study Section (MEDI), February 10-11, 2010 meeting
2009	Grant reviewer for the Alzheimer's Association's 2009 International Grant Program, April 2009
2009	Reviewer for the Challenge Grant applications, NIH CSR SBIB-V (58)R Challenge grant Panel #23, June 2009
2009	Vice Chair of NIH CSR Medical Imaging Study Section (MEDI), May 31- June 1, 2009
2009	Vice Chair of NIH CSR Medical Imaging Study Section (MEDI), June 2-3, 2009
2008	Vice Chair of NIH CSR Medical Imaging Study Section (MEDI), October 5-6, 2008
2008	Vice Chair of NIH CSR Clinical Molecular Imaging Study Section (MEDI-A, October 6-7, 2008
2008	Review Board Member for the Prostate Cancer Foundation of Australia (Prof. John Mills, Chair)
2008	Reviewer for NIH Small Business Innovation Research (SBIR) Topic 230 Phase II: Synthesis of Stable Isotope-Labeled Steroids as Internal Standards for the Measurement of Endogenous Steroid Hormones in Biologic Samples by Liquid Chromatography – Mass Spectrometry (LC-MS)
2007	Reviewer for NIH SBIR Topic 230 Phase I: Synthesis of Stable Isotope-Labeled Steroids as Internal Standards for the Measurement of Endogenous Steroid Hormones in Biologic Samples by Liquid Chromatography – Mass Spectrometry (LC-MS)
2007	Reviewer for the UNMC Drug Development Study Section in the Assistantship/Fellowship Competition
2005 - 2001	Review Board Member, AAAS Research Competitiveness Service
2004 - 2005	Grant reviewer for the National Institutes of Health, Center for Scientific Review Special Emphasis Panel on Radioimmunotherapy

2004	Grant reviewer for the National Institutes of Health, Diagnostic Radiology Study Section, Center for Scientific Review
2001	Ad hoc Grant reviewer for the Department of Energy Cell-Targeted Cancer Therapy Program
1993 - 1999	Ad hoc Reviewer for the US Army Medical Research and Materiel Command

EDITORIAL AND ADVISORY BOARDS

2021- 2022	Guest Editor for a special issue *Diagnostic, Prognostic and Predictive Markers in Pediatric Cancer* (this special issue belongs to the Section of *Diagnostics: Pathology and Molecular Diagnostics*)
2004 - present	Editorial Board Member, Current Medicinal Chemistry
2002 - 2020	Editorial Board Member, Letters in Drug Design and Discovery
2007 - 2018	Editorial Board Member, TO Medicinal Chemistry
2016 - 2018	Editorial Board Member, Cancer Research on Prevention and Treatment
2008 - 2014	Editorial Board Member, TO Nuclear Medicine Journal
2008 - 2009	Scientific Advisory Board Member, Peak Biosciences, Inc.
2008 - 2013	Editorial Board Member, TO Chemical and Biomedical Methods Journal
2011	Guest Editor, International Journal of Molecular Imaging

JOURNAL REVIEWER

Present - 1995	Journal of Nuclear Medicine
Present - 2000	several AACR publications including Molecular Cancer Therapeutics, Cancer Research and Clinical Cancer Research
Present - 2000	European Journal of Cancer
Present - 2000	Current Medicinal Chemistry
Present - 2000	Cancer Letters
Present - 2001	Immunotherapy
Present - 2004	Letters in Drug Design & Discovery
Present - 2009	International Journal of Radiation Oncology, Biology, Physics
Present - 2015	Cancer Research on Prevention and Treatment - Distinguished Reviewer

COMMITTEES

Present - 2008	Chair, Radiation Safety Committee, UNMC, Omaha, Nebraska
Present - 2006	Radiation Safety Committee member, UNMC, Omaha, Nebraska
Present - 2007	Scientific Review Committee, UNMC, Omaha, Nebraska
Present - 1993	Radioactive Drug Research Committee (on hold), UNMC, Omaha, Nebraska
1993 - 2001	UNMC Chemical and Radiation Safety Committee
1997	Steering Committee Member for the 10th International Symposium on Radiopharmacology, May 19-22, 1997, Genoa, Italy
1998	Organizer of The 1st Annual Retreat and Workshop on Drug Design and Delivery, Feb. 22, 1998, Omaha, Nebraska
1999	Member of the Working Group on Therapy of Pancreatic Cancer; Pancreas Cancer Think Tank, Sept. 16, 1999, Park City, Utah
1999 - 2009	Investigational Animal Care and Use Committee, UNMC, Omaha, Nebraska
2002 - 2004	Chair, Animal Facility Oversight Committee, UNMC, Omaha, Nebraska
2003 - 2007	Comparative Medicine System Development Steering Committee, UNMC, Omaha, Nebraska
2004 - 2007	Science and Technology Advisory Committee, UNMC, Omaha, Nebraska

2007	Chair, Radiation Oncology Promotion and Tenure Committee, UNMC, Omaha, Nebraska
2008	Review Board Member (Prof. John Mills, Chair), Prostate Cancer Foundation of Australia, Australia
2014	Member, Radiation Oncology Promotion and Tenure Committee, UNMC, Omaha, Nebraska
2016	Member of the search committee for the UNMC Executive Director of Environmental Health and Safety

COMMUNITY SERVICE

1998 - 2019	Founder, coordinator and participating faculty of the Radiation Oncology UNMC Summer Undergraduate Research Program
2008 - present	On-call Scientist for the AAAS Program on Scientific Responsibility, Human Rights and Law
2015 - present	Member, Breast Clinical Trial Working Group, Big 10 Cancer Research Consortium
2017 - present	Member, Gynecologic Clinical Trial Working Group, Big 10 Cancer Research Consortium
2017 - present	Member, Neuro-Oncology Clinical Trial Working Group, Big 10 Cancer Research Consortium
2004 - 1993	UNMC Radiation Health Center, Emergency Response Team, Omaha, Nebraska
1997 - 2002	Minority High School Student and Teacher Research Training Program, Participating Faculty (Dr. Terry Lawson, Leader), Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska

PATENTS AND DISCLOSURES

2020	10874752 US Patent. MIBG analogs and uses thereof. Baranowska-Kortylewicz J, Kortylewicz ZP. December 29, 2020
2019	PCT/US19/25813. Compositions and Methods for the Treatment and Imaging of Cancer. Baranowska-Kortylewicz J, Kortylewicz ZP. April 2019.
2018	62652543 US provisional patent application. Therapeutic and Imaging Agents for the Treatment and Diagnosis of Cancer. 18074P Serial No. 62/652,543. Baranowska-Kortylewicz J, Kortylewicz ZP. April 2018.
2018	20180256761 US patent application. MIBG analogs and uses thereof. Kortylewicz ZP, Baranowska-Kortylewicz J. http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=baranowska-kortylewicz.IN.&OS=IN/baranowska-kortylewicz&RS=IN/baranowska-kortylewicz. September 2018.
2017	WO2017053834A1Worldwide application. MIBG analogs and uses thereof. https://patents.google.com/patent/WO2017053834A1/ja. March 2017.
2017	20170151355 Amended patent application. Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer. Baranowska-Kortylewicz J, Kortylewicz ZP. June 2017.
2016	9,315,534 Radiologic agents for monitoring Alzheimer's disease progression and evaluating a response to therapy and processes for the preparation of such agents. Kortylewicz ZP, Baranowska-Kortylewicz J. April 2016.
2014	UNMC New Invention Notification 14018: *Rapid ultrasensitive method to detect and quantitate androgen receptor in cells and tissue.*
2010	UNMC New Invention Notification 11010: *Blood biomarker and rapid assays for gliomas and possibly other solid tumors*.

2009 Radiologic agents for monitoring Alzheimer's disease progression and evaluating a response to therapy and processes for the preparation of such agents. Baranowska-Kortylewicz J, Kortylewicz ZP. USPTO application number US 2009-0117041 A1; May 07, 2009

2008 UNMC New Invention Disclosure 09013. *Radioactive drugs for cancer diagnosis and therapy*. Baranowska-Kortylewicz J, Kortylewicz ZP.

2008 UNMC New Invention Disclosure 09011. *Sex hormone binding globulin: new target for ovarian cancer therapy*. Baranowska-Kortylewicz J.

2008 UNMC New Invention Disclosure 09005. *Radioactive derivatives for detection of multidrug resistance.* Baranowska-Kortylewicz J, Kortylewicz ZP.

2007 US patent 7,220,730. *Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer*. Baranowska-Kortylewicz J, Kortylewicz ZP. May 22, 2007

2007 UNMC New Invention Disclosure 07010. *Drugs for imaging of the Alzheimer's disease progression and response to therapy.* Kortylewicz ZP, Baranowska-Kortylewicz J.

2007 UNMC New Invention Disclosure 07022. *Radiopharmaceuticals for PET and SPECT imaging of thymidine kinase activity and cellular proliferation in cancer.* Kortylewicz ZP, Baranowska-Kortylewicz J.

2005 PCT/IB03/03 UNMC-Novartis patent 63177 series entitled *"Enhancing the Effect of Radioimmunotherapy in the Treatment of Tumors."* Baranowska-Kortylewicz J, Kurizaki T Abe M, Ostman A, Pietras K.

2002 UNMC New Invention Disclosure 02001: Use of ^{125}IUdR Glycosides in Systemic Administration for Antibody-Directed Enzyme Prodrug Delivery. Baranowska-Kortylewicz J, Kortylewicz ZP.

2002 UNMC New Invention Disclosure 02017: Effects of STI571 on Experimental Radioimmunotherapy of Colorectal Cancer. Baranowska-Kortylewicz J, Kurizaki T Abe M, Ostman A, Pietras K.

2001 WO0103745; January 18, 2001. *Therapy, prevention of recurrence and diagnosis of colorectal cancer with site-directed radiopharmaceuticals.* Kortylewicz ZP, Baranowska-Kortylewicz J

2000 UNMC New Invention Disclosure. *Increasing vascular permeability with response-selective agonists of human C5a*. Baranowska-Kortylewicz J, Sanderson S.

2000 UNMC New Invention Disclosure 00023. *Genetically engineered constructs for multiple tumor targeting (Pretargeting)*. Baranowska-Kortylewicz J, Pavlinkova G.

1999 UNMC New Invention Disclosure 99003. *Therapy, prevention of recurrence and diagnosis of colorectal cancer with site-directed radiopharmaceuticals.* Baranowska-Kortylewicz J, Kortylewicz ZP.

1995 U.S. Patent 5,468,853; *Synthesis of 5-radiohalo-2'-deoxyuridines*. Baranowska-Kortylewicz J. Nov. 21, 1995

1996 German Patent 68,922,489T2. *Verfahren zur herstellung von radioiodiertem pyrimidin*. Kassis AI, Baranowska-Kortylewicz J. Feb. 1, 1996

1995 Austrian Patent 122,050E. *Verfahren zur herstellung von radioiodiertem pyrimidin.* Kassis AI, Baranowska-Kortylewicz J. May 15, 1995

1995 German Patent 68,922,489C0. *Verfahren zur herstellung von radioiodiertem pyrimidin*. Kassis AI, Baranowska-Kortylewicz J. June 8, 1995

1995 EP Patent 403,544B1. *Method of making radioiodinated pyrimidine*. Designated countries: Austria, Belgium, Switzerland, Germany, France, United Kingdom, Italy, Liechtenstein, Luxembourg, The Netherlands, Sweden. Kassis AI, Baranowska-Kortylewicz J. May 3, 1995

1991 EP Patent 4,035,44A4. *Method of making radioiodinated pyrimidine.* Kassis AI, Baranowska-Kortylewicz J. April 10, 1991

1990 EP Patent 4,035,44A1. *Method of making radioiodinated pyrimidine.* Designated countries: Austria, Belgium, Switzerland, Germany, France, United Kingdom, Italy, Liechtenstein, Luxembourg, The Netherlands, Sweden. Kassis AI, Baranowska-Kortylewicz J. Dec. 1990

1989 WO Patent 8,907,106A1. *Method of making radioiodinated pyrimidine.* Designated countries: Austria, Belgium, Switzerland, Germany, France, United Kingdom, Italy, Japan, Luxembourg, The Netherlands, Sweden. Kassis AI, Baranowska-Kortylewicz J.

1989 U.S. Patent No. 4,851,520. Baranowska-Kortylewicz J, Kassis AI; *Radioiododemercuration of nucleotides and nucleosides.*

INVESTIGATIONAL NEW DRUG APPLICATIONS

IND 117,372 A first in man Phase I biodistribution, pharmacokinetics and dosimetry study of RISAD-P in patients diagnosed with prostate cancer.

IND 106,412 Role of F-18 fluorothymidine (FLT) ([F-18] FLT) in the Clinical Evaluation of Lymphomas and Primary Head and Neck Carcinomas: a Randomized Trial.

IND 36,948 160-91: An Evaluation of ^{123}IUdR for Imaging of Primary and Metastatic Liver Disease. 120-93: An Evaluation of 131I-Iododeoxyuridine (^{131}IUdR) for imaging of high-grade primary astrocytomas.

IND 44,763 An Evaluation of 123I-Iododexyuridine (^{123}IUdR) and 125I-Iododeoxyuridine (^{125}IUdR) for Imaging of Bladder Tumors and Autoradiography in diagnosis of bladder cancer.

IND 47,528 A phase I evaluation of iodine-125 iododeoxyuridine (^{125}IUdR) as a therapeutic agent for therapy of metastatic malignancy in the liver.

IND BB4187 Phase I study of chelated radiolabeled antiferritin in relapsed Hodgkin's disease.

CLINICAL TRIALS

IRB 120-93 (Tempero, Dalrymple) UNMC

A Phase I Evaluation of (^{131}IUdR and ^{123}IUdR for Imaging and Therapy of Metastatic Malignancies of the Liver.

MAB-9806 (Lydiatt) Intracel Corporation

A Phase I, II Dose Escalation Study of Radioimmunotherapy Using Indium In 111 and Yttrium Y 90 Labeled LiLo-16.88, a Human Monoclonal Antibody Conjugate Administered by Direct Intratumoral Injection in Patients with Recurrent Head and Neck Squamous Cell Cancer.

RIT-II-004 (Vose, Bierman) Coulter Pharmaceutical

Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy-Refractory Low-Grade B-Cell Lymphomas or Low Grade Lymphomas that Have Transformed to Higher Grade Histologies (BB IND 3323).

BB IND 4850 (Vose, Bierman) IDEC Pharmaceutical Corporation

A Multicenter, Open Label Trial to Evaluate the Efficacy and Safety of IDEC-Y2B8 Radioimmunotherapy in Relapsed or Refractory, Low Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma.

IND 47,528 (Tempero, Dalrymple) NCI

A phase I evaluation of iodine-125 iododeoxyuridine (125IUdR) as a therapeutic agent for therapy of metastatic malignancy in the liver.

CC93-91 (Tempero) Cytogen Corporation

Imaging of TAG-72 Positive Adenocarcinomas with Interferon-Gamma and ^{111}In-B72.3 Monoclonal Antibody: A Study to Evaluate Antigen Upregulation and Define Optimal Dose of Interferon-Gamma.

BB IND 5566 (Tempero) UNMC, NCI

Phase Ia/Ib Clinical Trial of Recombinant Gamma-Interferon and a Radioimmunoconjugate (^{90}Yttrium Mab CC49) in Patients with Gastrointestinal Adenocarcinomas.

MAB-9606 (McIntosh) PerImmune, Inc.

A Multi-Center Phase II Evaluation of Radioimmunoscintigraphy with OncoSPECt®/OV-Tc (Technetium Tc 99 Votumumab) in Patients with Ovarian Cancer.

MAB-9514 (Tempero, Dalrymple) PerImmune, Inc.

A Multi-Center Evaluation of OncoSPECT®/CR Colorectal (^{99m}Tc-88BV59H21-2V67-66) in Detection of Extrahepatic Metastases in Colorectal Cancer Patients Ovarian Cancer.

No number (Vose) UNMC

BEAC + 131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma.

CCBX001-048 (Vose) Corixa Corporation

A Multicenter Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients with Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma.

NCT00062894 (Vose, Bierman) GlaxoSmithKline

A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma.

IM-T-LL2-04 (Bireman, Vose) Immunomedics, Inc.

Phase I/II Clinical Trial of ^{131}Iodine-Mab LL2 in Patients with Recurrent Non-Hodgkin's Lymphoma.

IM-D-LL2-06 (Vose) Immunomedics, Inc.

The Utility of LymphoScan Imaging in the Detection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma (BB IND 3622).

BB IND 3809 (Tempero) Akzo Nobel

Radioimmunotherapy of Colorectal Carcinoma with OncoSpect (^{99m}Tc-88BV59), a Totally Human Monoclonal Antibody.

Neorex0001 (Tempero, Vose) NeoRx Corporation

A Phase I Study of Radiolabeled DOTA-Biotin Localization of Tumor Pretargeted by Murine B9E9 Antibody/Streptavidin Fusion Protein (B9E9Fusion) in Patients with Refractory or Relapsed Non-Hodgkin's Lymphoma.

NCT00004874 and CP-98-020 (Vose) Corixa Corporation, NCI, Coulter Pharmaceutical, Inc.

Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma.

NCT00615186 (Bierman) Bradmer Pharmaceuticals Inc.

A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme.

NCT00329030 (Vose) NHLBI, NCI

Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401).

NCT00006695 (Vose) NCI

BEAM Plus Iodine-131 Anti-B1 Antibody and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma.

NCT00315731 (Vose) GSK

A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma.

NCT00574509 (Vose) UNMC

BEAM+131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma.

NCT00006721 (Vose) Southwest Oncology Group, NCI, ECOG

A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas.

LR131-MM01 (Tarantolo, PI) Human Genome Sciences, Inc.

A phase 1 dosimetry and dose escalation study of Lymphorad-131 (LR131; Iodine-I-131-labeled B-lymphocyte stimulator) in patients with multiple myeloma.

NCT00031642 (Vose, Bierman) Biogen, UNMC

Phase I/II Study of IDEC-Y2B8 (Zevalin) for Post Transplant Relapses of B-Cell Non-Hodgkin's Lymphoma.

IND 36,948 120-93 (Dalrymple, Tempero) ACS, NE LB 595

An Evaluation of ^{123}IUdR for Imaging of Primary and Metastatic Liver Disease.

IND 36,948 190-91: (Dalrymple, Tempero) UNMC

An Evaluation of 131I-Iododeoxyuridine (131IUdR) for imaging of high-grade primary astrocytomas.

IND 44,763 (Dalrymple, Chiou) UNMC, NE LB 595

An Evaluation of 123I-Iododexyuridine (^{123}IUdR) and 125I-Iododeoxyuridine (^{125}IUdR) for Imaging of Bladder Tumors and Autoradiography in diagnosis of bladder cancer.

163-94 (Dalrymple, Chiou) UNMC

An Evaluation of 123I-Iododeoxyuridine (123IUdR) and 125I-Iododeoxyuridine (125IUdR) for Imaging of Bladder Tumors.

BB IND 4187 (Bierman, Dalrymple) NCI

Phase I Study of Radiolabeled Chelated Antiferritin in Relapsed Hodgkin’s Disease.

IND 47,528 (Dalrymple, McIntosh) UNMC

An Experimental Therapy Using 125/123IUdR (Iododeoxyuridine) for a Patient with a Diagnosis of Pesudomyxoma peritonei Secondary to Cancer of The Ovary.

OTHER CLINICAL STUDIES

024-14-EP (Coulter) UNMC

Butyrylcholinesterase as a druggable biomarker in neuroblastoma.

RESEARCH PUBLICATIONS

1. Baranowska-Kortylewicz J, Kortylewicz ZP, McIntyre EM, Sharp JG, Coulter DW. Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE deletion on the neuroblastoma growth in vitro and in vivo. J Pediatr Hematol Oncol. 2021 Sept 6. Online ahead of print. doi: 10.1097/MPH.0000000000002285 PMID: 34486544

2. Kortylewicz ZP, Coulter DW, Han G, Baranowska-Kortylewicz J. Radiolabeled (R)-(-)-5-iodo-3'-O-[2-(ε-guanidinohexanoyl)-2-phenylacetyl]-2'-deoxyuridine: A new theranostic for neuroblastoma. J Labelled Comp Radiopharm. 2020; 63:312-324. PMID: 32150284.
3. Baranowska-Kortylewicz J, Sharp JG, McGuire TR, Joshi S, Coulter DW. Alpha-Particle therapy for multifocal osteosarcoma: A hypothesis. Cancer Biother Radiopharm. 2020; 35:418-424. PMID: 32073902.
4. Kortylewicz ZP, Coulter DW, Han G, Baranowska-Kortylewicz J. Norepinephrine-transporter-targeted and DNA-co-targeted theranostic guanidines. J Med Chem. 2020; 63:2051-2073. PMID: 31268317. This article is included in the *Women in Medicinal Chemistry* Special Issue.
5. Kortylewicz ZP, Coulter DW, Baranowska-Kortylewicz J. In vitro and in vivo evaluation of radiolabeled methyl N-[5-(3'-halobenzoyl)-1H-benzimidazol-2-yl]carbamate for cancer radiotherapy. Drug Dev Res. 2020; 81:62-69. PMID: 31593323.
6. Kortylewicz ZP, Coulter DW, Baranowska-Kortylewicz J. Biological evaluation of a potential anticancer agent methyl N-[5-(3'-iodobenzoyl)-1H-benzimidazol-2-yl]carbamate. Cancer Biother Radiopharm. 2020; 35:16-25. PMID: 31687840.
7. Kortylewicz ZP, Baranowska-Kortylewicz J. Radiosynthesis of microtubule-targeted theranostic methyl N-[5-(3'-radiohalobenzoyl)-1H-benzimidazol-2-yl] carbamates. J Label Compd Radiopharm. 2018; 61:749–756.
8. Dalrymple GV, Kortylewicz ZP, Baranowska-Kortylewicz J. DNA-targeted molecular radiotherapy for ovarian cancer. New Horiz Transl Med. 2017; 4:52-53. https://doi.org/10.1016/j.nhtm. 2017. 11.001
9. Coulter DW, Boettner AD, Kortylewicz ZP, Enke SP, Luther JA, Verma V, Baranowska-Kortylewicz J. Butyrylcholinesterase as a blood biomarker in neuroblastoma. J Pediatric Hematol Oncol. 2017; 39:272-281. PMID: 28375942.
10. Kortylewicz ZP, Mack E, Enke CA, Estes KA, Mosley RL, Baranowska-Kortylewicz J. Preclinical evaluation of investigational radiopharmaceutical RISAD-P intended for use as a diagnostic and molecular radiotherapy agent for prostate cancer Prostate. 2015; 75:8-22. PMID: 25283970.
11. Han G, Kortylewicz ZP, Enke T, Baranowska-Kortylewicz J. Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies. Prostate. 2014; 74:1634-46. PMID: 25214432.
12. Yannam GR, Han B, Setoyama K, Yamamoto T, Ito R, Brooks JM, Guzman-Lepe J, Galambos C, Fong JV, Deutsch M, Quader MA, Yamanouchi K, Kabarriti R, Mehta K, Soto- Gutierrez A, Roy-Chowdhury J, Locker J, Abe M, Enke CA, Baranowska-Kortylewicz J, Solberg TD, Guha C, Fox IJ. A non-human primate model of human radiation-induced venocclusive liver disease and hepatocyte injury. Int J Rad Oncol Biol Phys. 2013 Int J Radiat Oncol Biol Phys. 2014. 88: 404-11. PMID: 24315566.
13. Baranowska-Kortylewicz J, Han G, Enke T, Mack E, Enke CE, Estes KA, Mosley RL, Kortylewicz ZP. Preclinical evaluation of an investigational radiopharmaceutical intended for use as a diagnostic and molecular radiation therapy agent for prostate cancer. Int J Radiation Onc Biol Phys 2014: 90:S87–S88.
14. Kortylewicz ZP, Kimura Y, Inoue K, Mack E, Baranowska-Kortylewicz J. Radiolabeled Cyclosaligenyl Monophosphates of 5-Iodo-2'-deoxyuridine, 5-Iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-Fluorothymidine for Molecular Radiotherapy of Cancer: Synthesis and Biological Evaluation. J Med Chem. 2012; 55:2649-71. PMID: 22339166.
15. Baranowska-Kortylewicz J. Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors. Immunotherapy. 2011; 3:491-4. PMID: 1463190.

16. Abe M, Kortylewicz ZP, Enke CA, Baranowska-Kortylewicz J. Activation of PDGFr-β signaling pathway after imatinib and radioimmunotherapy treatment in experimental pancreatic cancer. Cancers, 2011; 3:2501-2515. doi:10.3390/ cancers3022501. PMID: 24212821.
17. Kortylewicz ZP, Nearman J, Baranowska-Kortylewicz J. Radiolabeled 5-iodo-3'-O-(17β-succinyl-5α-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation. J Med Chem. 2009; 52:5124–5143. PMID: 19653647.
18. Kortylewicz ZP, Augustine AM, Nearman J, McGarry J, Baranowska-Kortylewicz J. Radioiodinated agents for imaging multidrug resistant tumors. Med Chem. 2009; 5:171-81. PMID: 19275716.
19. Baranowska-Kortylewicz J. Availability of molecular imaging and "personalized medicine.". J Nucl Med. 2009; 50:16N. PMID: 19139183.
20. Baranowska-Kortylewicz J, Nearman J, Kortylewicz ZP. Effect of sex hormone binding globulin on the development of ovarian cancer in mice. TO Cancer J. 2008; 2:59-65. DOI: 10.2174/1874079000802010059
21. Solberg TD, Nearman J, Mullins J, Li S, Baranowska-Kortylewicz J. Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2 and osteopontin in response to radiotherapy. Int J Rad Oncol Biol Phys. 2008; 72:918-926. http://www.redjournal.org/article/S0360-3016(08)02978-7/pdf. PMID: 19014781.
22. Kimura Y, Inoue K, Abe M, Nearman J, Baranowska-Kortylewicz J. PDGFR-β and HIF-1α inhibition with imatinib and radioimmunotherapy of experimental prostate cancer. Cancer Biol Ther. 2007; 6(11). PMID:17986854.
23. Baranowska-Kortylewicz J, Abe M, Nearman J, Enke CA. Emerging role of platelet-derived growth factor receptor-β inhibition in radioimmunotherapy of experimental pancreatic cancer. Clin Cancer Res. 2007; 13:299-306. PMID:17200369.
24. Nagata H, Nishitai R, Shirota C, Zhang JL, Koch CA, Cai J, Awwad M, Schuurman HJ, Christians U, Abe M, Baranowska-Kortylewicz J, Platt JL, Fox IJ. Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology. 2007; 132:321-9. PMID:17241882.
25. Baranowska-Kortylewicz J. Radioactive drugs in drug development research: quality assurance issues. Mini Rev Med Chem. 2007; 7:231-44. PMID:17346216.
26. TD Solberg, J Baranowska-Kortylewicz, J Nearman, J Mullins, S Li. Tumor Response to Hypofractionated Radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 69:S620-S621
27. Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, Paulsson J, Mosley RL, Enke CA, Ostman A. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005; 65:7824-31. PMID:17200369.
28. Baranowska-Kortylewicz J, Nearman J. DNA uptake of 131I-iododeoxyuridine. J Nucl Med. 2005; 46:898-9. PMID:15872365.
29. Wittel UA, Jain M, Goel A, Baranowska-Kortylewicz J, Kurizaki T, Chauhan SC, Agrawal DK, Colcher D, Batra SK. Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49. Biochem Biophys Res Commun. 2005; 329:168-76. PMID:15721289.
30. Ostman A, Pietras K, Hägerstrand D, Furuhashi M, Abe M, Robinson S, Wu Y, Hicklin DJ, Baranowska-Kortylewicz J, Nister M, Heldin CH, Rubin K. PDGF receptors as cancer drug targets. Ann Oncol. 2005; 26(S3):iii21–iii22. https://doi.org/10.1093/annonc/mdi604.
31. Kurizaki T, Abe M, Sanderson SD, Enke CA, Baranowska-Kortylewicz J. Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides. Mol Cancer Ther. 2004; 3:85-91. PMID:14749478.

32. Baranowska-Kortylewicz J, Abe M, Kurizaki T, Pietras K, Kortylewicz ZP, Nearman J, Mosley RL, Enke CA, Östman A. Enhancing radioimmunotherapy with the PDGFr-beta inhibitor: imaging and tumor response studies. Eur J Cancer. 2004; 2:90.
33. Abe M, Lai J, Kortylewicz ZP, Nagata H, Fox IJ, Enke CA, Baranowska-Kortylewicz J. Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves. Bioconjug Chem. 2003; 14:997-1006. PMID:13129404.
34. Pavlinkova G, Batra SK, Colcher D, Booth BJM, Baranowska-Kortylewicz J. Constructs of Biotin Mimetic Peptide with CC49 Single-Chain Fv Designed For Tumor Pretargeting. Peptides, 2003, 24:353-362. PMID: 12732332.
35. Kurizaki T, Okazaki S, Sanderson SD, Tempero MA, Colcher D, Enke CA, Baranowska-Kortylewicz J. Potentiation of radioimmunotherapy of colorectal cancer with novel vasoactive constructs. J. Nucl. Med., 2002; 43:957-67. PMID:12097469.
36. Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Booth BJM, Batra S. Biodistribution and radioimmunolocalization studies of human colon carcinoma xenografts with technetium-99m-labeled divalent and tetravalent CC49 single chain constructs. J Nucl Med. 2001; 42:1519-27. PMID: 11585867.
37. Goel A, Baranowska-Kortylewicz J, Colcher D, Booth BJM, Pavlinkova G, Batra SK. Single-dose versus fractionated radioimmunotherapy of human colon carcinoma using 131I-labeled multivalent CC49 single-chain fragments. Clin. Cancer Res., 2001; 7:175-184. PMID:11205906.
38. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJM, Pavlinkova G, Batra SK. Genetically-engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application. Cancer Res. 2000; 60:6964-6971. PMID:1115639.
39. Goel A, Beresford GW, Colcher D, Pavlinkova G, Booth BJM, Baranowska-Kortylewicz J, Batra SK. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification and characterization. J. Biochem. 2000; 127:829-836. PMID:10788792.
40. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. High dose therapy with ^{90}Yttrium labeled monoclonal antibody CC49: A phase I trial. Clinical Cancer Res., 2000; 6:3095-3102. PMID:10955789.
41. Chiou R, Baranowska-Kortylewicz J, Dalrymple GV, Holdeman K, Harrison K, Schneiderman M. Tumor localization and systemic absorption of intravesical instillation of radioiodinated iododeoxyuridine. J Urol., 1999; 162:58-62. PMID:10379740.
42. Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KC, Cook CU, Sahu SK, Black PMcL. 5-[^{125}I]Iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med., 1998; 39:1148-1154. PMID:9669385.
43. Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S. Stabilization of vasoactive intestinal peptide by lipids. J Pharm Exp Ther. 1998; 285:753-758. PMID:9580623.
44. Baranowska-Kortylewicz J, Kortylewicz ZP, Hoffman D, Dalrymple GV. Prodrugs in a site-selective delivery of radiopharmaceuticals. Q J Nucl Med. 1997; 41:127-139. PMID:9203852.
45. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. J Clin Immunol. 1997, 17:96-106. PMID:9049790.
46. Sahu SK, Kortylewicz ZP, Baranowska-Kortylewicz J, Taube RA, Adelstein SJ, Kassis AI. Strand breaks following the decay of ^{125}I in close proximity to plasmid pBR322 DNA. Rad Res. 1997; 147:401-408. PMID: 9092918.
47. Leichner PK, Akabani G, Colcher DM, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Patient-specific dosimetry of indium-

111/yttrium-90-labeled monoclonal antibody CC-49. J Nucl Med. 1997; 38:512-516. PMID:9098192.

48. Mariani G, Collecchi P, Baldassarri S, Di Luca L, Buralli S, Fontanini G, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. Tumor uptake and mitotic activity pattern of 5-[^{125}I]iodo-2'-deoxyuridine after intravesical infusion in patients with bladder cancer. J Nucl Med. 1996, 37:13S-19S. PMID:8676197.
49. Kassis AI, Tumeh SS, Wen PYC, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Baily NO, Castranovo FP, Mariani G, Black PMcL, Adelstein SJ. Intratumoral administration of 5-[^{123}I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996, 37:19S-22S. PMID:8676198.
50. Mariani G, Di Sacco S, Volterrani D, Di Luca L, Buralli S, Di Stefano R, Baranowska-Kortylewicz J, Bonora D, Mateucci F, Ricci S, Bellina CR, Falcone A, Salvadori PA, Mosca F, Adelstein SJ, Kassis AI. Tumor targeting by intra-arterial infusion of 5-[^{123}I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med. 1996, 37:22S-25S. PMID:8676199.
51. Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, Holdeman KP, Sharp JG, Cohen SM, Schneiderman MH, Lieberman RP, Clausen SR, Hoffman D, Lai J, Schneiderman GS. On the Safety of 5-[^{125}I]Iodo-2'-deoxyuridine. Pre-Clinical Evaluation in Swine. Acta Oncologica. 1996, 35:925-933. PMID:9004773.
52. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH. Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. Radiolabeled iododeoxyuridine: Safety evaluation. J Nuc Med. 1996, 37:13S-16S. PMID:8676196.
53. Baranowska-Kortylewicz J, Kortylewicz ZP, Hoffman D, Winoto A, Lai J, Dalrymple GV. Colon-specific prodrugs of 5-radioiodo-2'-deoxyuridine. Acta Oncologica. 1996, 35:959-964. PMID:9004778.
54. Mariani G, Di Sacco S, Bonini R, Di Luca L, Buralli S, Bonora D, Ricci S, Baranowska-Kortylewicz J, Adelstein SJ, Falcone A, Kassis AI. Biochemical modulation of 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[^{125}I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer. Acta Oncologica. 1996; 35:951-945. PMID:9004775.
55. Sahu SK, Kassis AI, Makrigiorgos GM, Baranowska-Kortylewicz J, Adelstein SJ. The effects of indium-111 decay on pBR322 DNA. Radiat Res. 1995, 141:193-198. PMID:7838958.
56. Makrigiorgos GM, Bump E, Huang C, Baranowska-Kortylewicz J, Kassis AI. A fluorometric method for the detection of copper-mediated hydroxyl free radicals in the immediate proximity of DNA. Free Radical Biol Med. 1995; 18:669-678. PMID:7750791.
57. Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie P, Adelstein SJ, Kassis AI. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med. 1995, 37:315-320. PMID:8667069.
58. Baranowska-Kortylewicz J, Helseth LD, Lai J, Schneiderman MH, Schneiderman GS, Dalrymple GV. Radiolabeling kit/generator for 5-radiohalogenated uridines. J Label Compds Radiopharm. 1994; 34:513-521.
59. Makrigiorgos GM, Folkard M, Huang C, Bump E, Baranowska-Kortylewicz J, Sahu SK, Michael BD, Kassis AI. Quantification of radiation-induced hydroxyl radicals within nucleohistones using a molecular fluorescent probe. Radiat Res. 1994; 138:177-185. PMID:8183987.
60. Mariani G, Di Sacco S, Volterrani D, Matteucci F, Di Luca L, Buralli S, Baranowska-Kortylewicz J, Di Stefano R, Ricci S, Bellina CR, Falcone A, Salvadori PA, Mosca F, Adelstein SJ, Kassis AI. Tumor targeting with 5-[^{123}I]iodo-2'-deoxyuridine infused into the hepatic artery of patients with liver metastases from colorectal cancer. J Nucl Biol Med. 1994; 38:265-267.

61. Kortylewicz ZP, Baranowska-Kortylewicz J, Adelstein SJ, Carmel AD, Kassis AI. Radiolabeled biotin amides from triazenyl precursors: Synthesis, binding, and in vivo properties. J Label Compds Radiopharm. 1994; 34:1129-1146. ISSN:0362-4803.
62. Makrigiorgos GM, Bump E, Huang C, Baranowska-Kortylewicz J, Kassis AI. Accessibility of nucleic acid-complexed biomolecules to hydroxyl radicals correlates with their conformation: a fluorescence polarization spectroscopy study. Int J Radiat Biol. 1994; 66:247-257. PMID:7930827.
63. Baranowska-Kortylewicz J, Kassis AI. Labeling of sulfhydryl groups in intact mammalian cells with coumarins. Bioconjugate Chem. 1993; 4:305-307. PMID:8218488.
64. Baranowska-Kortylewicz J, Adelstein SJ, Kassis A.I. Labeling of immunoglobulins with bifunctional, sulfhydryl-selective, and photoreactive coumarins. Bioconjugate Chem. 1993; 4:300-304. PMID:8218487.
65. Mariani G, Cei A, Collecchi P, Baranowska-Kortylewicz J, Van den Abbeele AD, Di Luca L, Di Stefano R, Viacava P, Ferdeghini EM, Di Sacco SD, Salvadori PA, Bevilacqua G, Adelstein SJ, Mosca F, Kassis AI. Tumor targeting in vivo and metabolic fate of 5-[^{125}I]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med. 1993; 34:1175-1183. PMID:8315499.
66. Makrigiorgos GM, Baranowska-Kortylewicz J, Bump E, Sahu SK, Berman RM, Kassis AI. A method for detection of hydroxyl radicals in the vicinity of biomolecules using radiation-induced fluorescence of coumarin. Int J Radiat Biol. 1993; 63:445-458. PMID:8096857.
67. Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco PA, Adelstein SJ, Bevilacqua G, Kassis AI. Tumor targeting potential and metabolism of 5-[^{125}I]iodo-2'-deoxyuridine injected intratumorally in patients with gastrointestinal or breast cancers. Ann N Y Acad Sci. 1993; 698:204-11. PMID: 8279758.
68. Vannucci L, Mariani G, Di Stefano R, Cei A, Di Luca L, Collecchi P, Baranowska-Kortylewicz J, Giulianotti PC, Guadagni A, Van den Abbeele AD, Salvadori PA, Bevilacqua G, Mosca F, Adeistein SJ, Kassis AI. Intratumoral injection of 5-125I-iodo-2'-deoxyuridine in patients with colon cancer. J R Coll Surg Edinb. 1992:282-283.
69. Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, Berman RM, Adelstein SJ, Kassis AI. 5-[^{123}I]Iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys. 1991; 21:1541-1551. PMID:1938564.
70. Makrigiorgos GM, Berman RM, Baranowska-Kortylewicz J, Bump E, Humm JL, Adelstein SJ, Kassis AI. DNA damage produced in V79 cells by DNA-incorporated ^{123}IUdR: A comparison with ^{125}IUdR. Radiat Res. 1991, 129:309-314. PMID:1542718.
71. Baranowska-Kortylewicz J, Kortylewicz ZP. Radioiodination of 7-methoxy and 6,7-dimethoxy-4-bromomethylcoumarins. J Labelled Comp Radiopharm. 1991; 29:1301-1307. ISSN:0362-4803.
72. Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, Van den Abbeele AD, Mariani G, Ito S. Potential for tumor therapy with iodine-125-labeled immunoglobulins. Int J Rad Appl Instrum B. 1991; 18:43-4. PMID:2010304.
73. Mariani G, Ito S, Baranowska-Kortylewicz J, Venkateshan CN, Van den Abbeele AD, Eisenbarth GS, Adelstein SJ, Kassis AI. Capping and internalization of a monoclonal antibody-surface antigen complex: A possible mode of interaction of monoclonal antibodies and tumor cells. J Nucl Biol Med. 1991; 35:111-119. PMID:1932178.
74. Mariani G, Guadagni A, Cei A, Van den Abbeele AD, Bevilacqua G, Salvadori P, Di Stefano R, Baranowska-Kortylewicz J, Adelstein SJ, Mosca F, Kassis AI. Fate of 5-125I-iodo-2'-deoxyuridine injected intratumorally in patients with colon cancer. J Nucl Med. 1991; 32:1082-1083.
75. Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. 5-Iodo-2'-deoxyuridine-protein conjugates: Synthesis and enzymatic degradation. Selective Cancer Therapeutics. 1990; 6:1-14. PMID:2343200.

76. Makrigiorgos GM, Ito S, Baranowska-Kortylewicz J, Vinter DW, Iqbal A, Van den Abbeele AD, Adelstein SJ, Kassis AI. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: Experimental evidence and dosimetric implications. J Nucl Med. 1990; 31:1358-1363. PMID:2384804.
77. Baranowska-Kortylewicz J, Berman RM, Kaldany A, Eisenbarth GS, Kassis AI. Immunoradiometric assay for antibodies recognizing antigenic gangliosides. J Nucl Med Allied Sci. 1990; 34:34-41. PMID:2384823.
78. Smith SV, Lambrecht RM, Van Den Abbeele, Baranowska-Kortylewicz J, Jones PL, Adelstein, SJ, Kassis AI. A new three-step strategy using the avidin-biotin system for radioimaging tumours. J Label Compd Radiopharm. 1994; 35:392-394.
79. Makrigiorgos G, Baranowska-Kortylewicz J, Van den Abbeele AD, Ito S, Adelstein SJ, Kassis AI. Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: Dosimetry at the cellular level and comparison with conventional dosimetry. Radiat Prot Dosim. 1990; 31:319-324. Online ISSN 1742-3406; print ISSN 0144-8420.
80. Kassis AI, Van den Abbeele AD, Wen PYC, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the Auger electron emitting thymidine analog 5-[$^{123/125}$I]-iodo-2'-deoxyuridine in rat brain tumors: Diagnostic and therapeutic implications in humans. Cancer Res. 1990; 50:5199-5203. PMID:2379179.
81. Makrigiorgos G, Kassis AI, Baranowska-Kortylewicz J, McElvany KD, Welch MJ, Sastry KSR, Adelstein SJ. Radiotoxicity of 5-[^{123}I]iodo-2'-deoxyuridine in V79 cells: A comparison with 5-[^{125}I]iodo-2'-deoxyuridine. Radiat Res. 1989; 118:532-539. PMID:2727274.
82. Nelson K, Baranowska-Kortylewicz J, Van Nagell JR. Gallion HH, Donaldson ES, Kenady DE, McRoberts WP, Pavlik EJ. Intermolecular engagement of estrogen receptors indicated by the formation of a high molecular weight complex during activation. Biochemistry 1989; 28:9741-9749. PMID:2514808.
83. Baranowska-Kortylewicz J, Kinsey BM, Layne WW, Kassis AI. Radioiododemercuration: A simple synthesis of 5-[$^{123/125/127}$I]iodo-2'-deoxyuridine. Appl Radiat Isot. 1988; 39:335-341. PMID:2838439.
84. Baranowska-Kortylewicz J, Nelson K, Pavlik EJ, Van Nagell JR, Gallion HH, Donaldson ES, Kenady DE. Identification of a very large nuclear estrogen receptor complex. Endocrinology. 1987; 120:2189-2191. PMID: 3569129.
85. Pavlik EJ, Van Nagell JR, Nelson K, Gallion H, Donaldson ES, Kenady DE, Baranowska-Kortylewicz J. Antagonism to estradiol in the mouse: Reduced entry of estrogen receptor complexes with 4-hydroxytamoxifen into Mg^{+2}-soluble chromatin fraction. Endocrinology. 1986; 118:988-994. PMID:2422013.
86. Baranowska-Kortylewicz J, Pavlik EJ, Smith WT, Flanigan RC, Van Nagell JR, Ross D, Kenady DE. Dichloro-(6-aminoethylaminopurine)-platinum(II) and its hydroxy analogues: Synthesis and preliminary evaluation. Inorganica Chim Acta. 1985; 108:91-98. ISSN:0020-1693.

PRESENTATIONS AND PEER-REVIEWED ABSTRACTS AT PROFESSIONAL MEETINGS

1. Baranowska-Kortylewicz J, Coulter DW, Kortylewicz ZP. Making better drugs for children with cancer. 2nd Annual Pediatric Cancer Research Group Symposium. Truhlsen Event Center. Omaha, NE August 26-27, 2019.
2. Baranowska-Kortylewicz J, Han G, Coulter DW, Kortylewicz ZP. Norepinephrine transporter-targeted and DNA-co-targeted theranostic guanidines. 17th annual Pediatric Research Forum. Children's Hospital and Medical Center, Omaha, NE. May 9-10, 2019.
3. Baranowska-Kortylewicz J, Kortylewicz ZP, Coulter DW. Butyrylcholinesterase and *BCHE* Gene: A Druggable Target and Prognostics Biomarker in Cancer. International Conference on Disease

Biomarkers and Precision Medicine. Houston, TX. Oct. 22-24, 2018. DBPM-2018 Abstract Book, 2018:8.

4. Kortylewicz, ZP, Dalrymple GV, Baranowska-Kortylewicz J. DNA-targeted molecular radiotherapy for ovarian cancer. 5th Annual European Congress on Clinical & Translational Sciences (EUSTM-2017). October 20-22, 2017.
5. Greenwood K, McGuire TR, Coulter D, McIntyre E, Chaturvedi NK, Kortylewicz ZP, Joshi SS, Chen X, Sharp JG, Baranowska-Kortylewicz J. Butyrylcholinesterase (BChE) expression as a marker of cellular proliferation across neuroblastoma cells lines: new prognostic marker and therapeutic target. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther. 2015; 14(12 Suppl 2); A127.
6. Enke T, Han G, Abe M, Kortylewicz ZP, Baranowska-Kortylewicz J. Molecular radiation therapy in experimental model of advanced prostate cancer using internalizable monoclonal antibody. Int J Radiation Onc Biol Phys 2014: 90:S810.
7. Baranowska-Kortylewicz J, Han G, Enke T, Mack E, Enke CE, Estes KA, Mosley RL, Kortylewicz ZP. Preclinical evaluation of an investigational radiopharmaceutical intended for use as a diagnostic and molecular radiation therapy agent for prostate cancer. Int J Radiation Onc Biol Phys 2014: 90:S87–S88.
8. Baranowska-Kortylewicz J. Androgen receptor-targeted molecular radiotherapy of prostate cancer. Greater Omaha Radiation Oncology Conference. GO ROC 2013. October 19, 2013. Omaha, NE.
9. Yannam G, Han B, Setoyama K, Yamamoto T, Ito R, Brooks J, Guzman-Lepe J, Galambos C, Fong J, Deutsch M, Quader M, Yamanouchi M, Mehta K, Soto-Gutierrez A, Roy-Chowdhury J, Locker J, Abe M, Enke C, Baranowska-Kortylewicz J, Solberg T, Guha C, Fox I. Tolerable limits to whole liver irradiation in non-human primates. Hepatology. 2012; 56:1674.
10. Kortylewicz ZP, Nearman J, Baranowska-Kortylewicz J. Drugs for imaging Alzheimer's disease. Molecular Neuroimaging Symposium. National Institutes of Health. Bethesda, May 6-7, 2010. J Nucl Med. 2010; 51:830.
11. Ramaekers RC, Elkahwaji J, Reed E, Ganti A, Wang J, Grem J, Baranowska-Kortylewicz J, Hauke R. Phase I study of imatinib in combination with gemcitabine and capecitabine. 2009 ASCO, May 29-June 02, 2009. J Clin Oncol. 2009; 15S: e13523-e13523.
12. Juweid ME, Buck AK, Baranowska-Kortylewicz J. Validation of 18F-fluorothymidine (FLT) as in vivo molecular probe for measurement of tumor DNA repair synthesis. 2009 SNM Annual Meeting, Toronto, June 13-17, 2009. J Nucl Med. 2009; 50:636.
13. Juweid ME, Buck AK, Baranowska-Kortylewicz J. Measurement of DNA Repair Synthesis Using Radiolabeled Thymidine Analogs (RTAs): Implications for in Vivo Imaging of DNA Repair. Annual Congress of the European Association of Nuclear Medicine; 2008; EANM'08 Munich, Germany. Eur J Nuc Med Mol Imag. 2008; 35:S390.
14. Juweid ME, Buck AK, Baranowska-Kortylewicz J. Validation of the use of radiolabeled thymidine analogs (RTAs) for measurement of DNA repair synthesis as prerequisite for their utilization as in vivo imaging probes of DNA repair. 2008 World Molecular Imaging Congress (WMIC 2008); September 10-13, 2008, Nice, France.
15. Juweid ME, Buck AK, Baranowska-Kortylewicz J. Can radiolabeled thymidine analogs be used as in vivo probes of DNA repair synthesis? Annual Meeting of the Society of Nuclear Medicine; June 14-18, 2008, New Orleans, LA. Can radiolabeled thymidine analogs (RTAs) be used as in vivo probes of DNA repair synthesis? J Nuc Med. 2008; 49:334P.
16. Solberg TD, Baranowska-Kortylewicz J, Nearman J, Mullins J, Li S. Tumor response to hypofractionated radiotherapy. Int J Radiat Oncol Biol Physics. 2007; 69:S620-621.

17. Baranowska-Kortylewicz J, Abe M, Nearman J, Mosley RL, Pavlinkova G, Enke CA. Antigen-independent methods to improve radioimmunotherapy. IMPaCT Proceedings. 2007; 196-197.
18. Abe M, Nearman J, Mosley RL, Pavlinkova G, Enke CA, Baranowska-Kortylewicz J. Outcome of radioimmunotherapy in experimental prostate cancer in response to transient increase of vascular permeability. AACR Special Conference: Innovations in Prostate Cancer Research. San Francisco December 6-9, 2006.
19. Baranowska-Kortylewicz J, Abe M, Kortylewicz ZP, Nearman J, Enke CA. CD88 agonist peptides to improve radioimmunotherapy of prostate cancer. 18th Polish Peptide Symposium. Published by Faculty of Chemistry, University of Wrocław, Wrocław, 2005. ISBN 83-60043-00-0.
20. Ostman A, Pietras K, Hagerstrand D, Furuhashi M, Abe M, Robinson S, Wu Y, Hicklin DJ, Baranowska-Kortylewicz J, Nister M, Heldin CH, Rubin K. PDGF receptors as cancer drug targets. 3rd International Symposium in Targeted Anticancer Therapies, 3-5 March, 2005: Amsterdam, The Netherlands.
21. Baranowska-Kortylewicz J, Abe M, Kotaro I, Norman J, Enke CA. Consequences of supplementing radioimmunotherapy with erythropoietin. The Society of Nuclear Medicine 52nd Annual Meeting, June 18-22, 2005; Toronto, Canada.
22. Baranowska-Kortylewicz J.; Abe M.; Kurizaki T.; Pietras K.; Kortylewicz Z.P.; Nearman J.; Mosley R.L.; Enke C.A.; Östman A. Abstract 295: Enhancing radioimmunotherapy with the PDGFr-beta inhibitor: imaging and tumor response studies. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 28 September - 1 October 2004, Geneva, Switzerland. On line at http://ex2.excerptamedica.com/ciw-04ena; 2004.
23. Östman A, Hägerstrand D, Pietras K, Furuhashi M, Wu Y, Hicklin DJ, Buchdunger E, Abe M, Nister M, Baranowska-Kortylewicz J, Heldin CH. Abstract 363: Targeting of PDGF receptors; combination effects in various solid tumors and identification of a PDGF dependent brain tumor subset. Eur J Cancer. 2004; 8:109. on line at http://ex2.excerptamedica.com/ciw-04ena; 2004.
24. Abe M, Nearman J, Kortylewicz ZP, Boska M, Pavlinkova G, Mosley RL, Baranowska-Kortylewicz J. CD88-Dependent methods to improve radioimmunotherapy of prostate cancer. EOARTC-AACR-NCI International Conference. Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Geneva, Oct. 2004.
25. Chauhan SC, Jain M, Baranowska-Kortylewicz J, Batra SK. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single chain constructs of the pancarcinoma monoclonal antibody CC49. Annual AACR Meeting, Toronto, Canada, 2003.
26. Baranowska-Kortylewicz J, Abe M, Kurizaki T, Pietras K, Ostman A, Kortylewicz ZP, Enke CA. Effects of STI571on radioimmunotherapy of colorectal cancer. AACR-NCI-EORTC International Conference. Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. 2003; 170.
27. J Baranowska-Kortylewicz, M Abe, T Kurizaki, K Pietras, A Ostman, ZP Kortylewicz, CA Enke. Effects of STI571 on radioimmunotherapy of colorectal cancer. Clin Cancer Res. 2003; 9:6189S.
28. Baranowska-Kortylewicz J, Kortylewicz ZP, Kurizaki T, Nearman J, Enke CA. Radioactive drugs based on targeting of specific receptors and cell cycle status for treatment of breast cancer. Era of Hope Abstracts 2002; Drug Design and Development. Published on line at www.cdmrp.army.mil/ bcrp/era/abstracts2002/P16_ Drug_Design_and_Development/P16_combined.pdf .
29. Kurizaki T, Sanderson SD, Colcher D, Enke CA, Tempero M, Baranowska-Kortylewicz J. Potentiation of radioimmunotherapy by a response-selective agonist of human C5a. J Nucl Med. 5(S):1364; 2001.

30. Kortylewicz ZP, Kurizaki T, Augustine AM, McGarry J, Nearman J, Franks S, Dalrymple GV, Enke CA, Baranowska-Kortylewicz J. Radioiodinated agent for imaging of multidrug resistant tumors. J. Nucl. Med. 5(S):1068; 2001.
31. Augustine SC, Norenberg JP, Tempero MA, Gobar LS, Devish KM, Colcher DM, Baranowska-Kortylewicz J, Rutar FJ. Evaluation of I-131 HuCC49ΔC_H2 monoclonal antibody for translational to clinical studies. American Pharmaceutical Association, Dec. 4-6, 2000, Las Vegas.
32. Goel A, Colcher D, Augustine S, Baranowska- Kortylewicz J, Booth BJ, Pavlinkova G, Tempero M, Batra SK. Multivalent Single-chain Fv of the Monoclonal Antibody CC49 for the Diagnosis and Therapy of Cancer. July 04 - 07, 2000, Chantilly, VA, 8th Annual SPORE Workshop.
33. Baranowska-Kortylewicz J, Kortylewicz ZP, Roy H, Enke CA, Dalrymple GV. Arrest of colorectal carcinogenesis by oral prodrugs of 5-[125I]iodo-2'deoxyuridine: A nuclear oncology approach. European Congress of Nuclear Medicine, Paris, France, Sept. 2 - 6, 2000 (selected for "*Highlights Lecture*").
34. Kurizaki T, Okazaki S, Colcher D, Tempero MA, Sanderson S, Baranowska-Kortylewicz J. Novel Immunoconstructs Designed to Enhance Vascular Permeability of Solid Tumor. July 04 - 07, 2000, Chantilly, VA, 8th Annual SPORE Workshop.
35. Batra SK, Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine SC, Booth BJ, Pavlinkova G, Tempero MA. Multivalent Single Chain Antibody Constructs of the Pancarcinoma Monoclonal Antibody CC49: Engineering, Pharmacokinetics, Biodistribution, and Therapy. 2000 DOE Nuclear Medicine Program Workshop. Radiopharmaceutical Therapy Section. October 17-20, 2000; Williamsburg, Virginia.
36. S Augustine, MA Tempero, LS Gobar, K Devish, D Colcher, J Baranowska-Kortylewicz, F Rutar, J Norenberg. Radiolabeling, quality testing and in vitro stability evaluation of I-131 HuCC49 Delta C (H) 2 monoclonal antibody. J Nucl Med. 2000; 41:252P.
37. Augustine S, Tempero MA, Gobar LS, Devish K, Colcher D, Baranowska-Kortylewicz J, Rutar F, Norenberg J. Radiolabeling, quality testing and in vitro stability evaluation of 131I-HuCC49ΔCH_2 monoclonal antibody. 47th Annual Meeting of the Society of Nuclear Medicine, St. Louis, June 3 - 7, 2000, abstract number 1109.
38. Wittel UA, Kurizaki T, Goel A, Booth BJM, Agrawal DK, Baranowska-Kortylewicz J, Batra SK. Engineering and characterization of a CC49 single-chain Fv-angiotensin II fusion constructs for improved tumor targeting. Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE 68198; Creighton University, Omaha, NE 68178, APA Meeting, June, 2001.
39. Gobar LS, Lydiatt WM, Simpson S, Klein JL, Leischner P, Baranowska-Kortylewicz J. Radioimmunotherapy with yttrium by intratumoral injection: Dosimetry and safety. J Nucl Med. 2000; 41:238P.
40. Baranowska-Kortylewicz J, Kortylewicz ZP, Hoffman D, Enke CA, Dalrymple GV. Bioreversible prodrugs for cancer radiotherapy with unsealed sources. Int J Radiat Oncol Biol Physics. 1999; 45:416. ASTRO. San Antonio, Texas, October 31 - Nov. 04, 1999.
41. Okazaki S, Baranowska-Kortylewicz J, Sanderson SD, Tempero MA, and Colcher D. Increasing vascular permeability with constructs of MAb B72.3 and C5a analog peptide. SPORE Retreat, Nebraska City, Nebraska, Aug. 19 - 21, 1999.
42. Baranowska-Kortylewicz J, Kortylewicz ZP, Dalrymple GV. Therapy of colorectal cancer with oral prodrugs of [^{125}I]iodo-2'-deoxyuridine. 7th SPORE Investigators' Workshop. Rockville, Maryland, July 11 - 13, 1999.
43. Baranowska-Kortylewicz J, Hoffman D, Lai J, Stark D, Dalrymple GV. Novel red blood cell-based imaging agents. European J. Nucl. Med. 1998; 25:878. Joint World Federation of Nuclear Medicine

and Biology and European Association of Nuclear Medicine Congress. Berlin, Aug. 30 - Sept. 4, 1998.

44. Chiou R, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Harrison KA, Schneiderman MH, Lai J, Schmidt BA, Taylor RJ. Tumor localization and systemic absorption of intravesical radio-iodinated iododeoxyuridine (IUdR) in bladder cancer patients. American Urological Association, Inc. 1999 Annual Meeting, Dallas Texas.
45. Baranowska-Kortylewicz J, Kortylewicz ZP, Toth B, Hoffman D. Radionuclide therapy of colorectal cancer with oral ^{125}IUdR. European J. Nucl. Med. 1998; 25:978. Joint World Federation of Nuclear Medicine and Biology and European Association of Nuclear Medicine Congress. Berlin, Aug. 30 - Sept. 4, 1998.
46. Chiou RK, Baranowska-Kortylewicz J, Dalrymple GV, Holdeman KP, Schneiderman MH, Harrison KA, Schmidt BA, Taylor RJ. Clinical trial of intravesical instillation of radioiodinated iododeoxyuridine for bladder cancer. 77th Annual Meeting of American Urologic Association, Cancun, Mexico, Oct. 30-Nov. 04, 1998.
47. Baranowska-Kortylewicz J, Kortylewicz ZP, Hoffman D. Prodrugs for intracellular delivery of ^{125}IUdR monophosphates. Q J Nucl Med. 1997; 41(Supplement):11. 10th International Symposium on Radiopharmacology. Rapallo, Genoa (Italy) May 19 - 22, 1997.
48. Baranowska-Kortylewicz J. Prodrugs in site-selective delivery of radiopharmaceuticals. Q J Nucl Med 1997; 10th International Symposium of Radiopharmacology. Rapallo, Genoa, Italy, May 19 - 22, 1997.
49. Baranowska-Kortylewicz J, Chiou RK, Chen Q, Lai J. Development of monoclonal antibody-interleukin-2 conjugate for renal cancer. J Urology, 1997; 157(S):29. American Urological Association 1997 Annual Meeting. New Orleans.
50. Leichner PK, Lydiatt D, Lydiatt W, Colcher D, Johansson S, Augustine S, Baranowska-Kortylewicz J, Harrison KA, Akabani G, Klein JL, Herpst JM, Hanna MG. Therapeutic potential of Yttrium-90 labeled human monoclonal antibody (^{90}Y-LiLo-16.88) in patients with head and neck squamous cell cancer. Tumor Targeting. 1996; 2:173. The Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer. October 10-12, 1996, Princeton, NJ.
51. Leichner PK, Akabani G, Colcher DM, Harrison KA, Hawkins WG, Baranowska-Kortylewicz J, Eckblade M, Augustine SC, Tempero MA. Patient-specific dosimetry of In-111/Y-90-labeled monoclonal antibody CC49. J Nucl Med. 1996; 37(S):90P. The Society of Nuclear Medicine 43rd Annual Meeting. Colorado, June 6-6, 1996.
52. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Dalrymple G, Colcher D. Phase Ia/Ib clinical trial of radioimmunoconjugate (^{90}Yttrium MAb CC49) in patients (pts) with gastrointestinal adenocarcinomas. American Association for Cancer Research Annual Meeting, 1996.
53. Baranowska-Kortylewicz J, Colcher D, Srivastava SC, Joshi V, Kolsky K, Mausner L, Dalrymple GV, Tempero MA. Pre-clinical evaluation of monoclonal antibody CC49 labeled with scandium-47. J Nucl Med. 1996; 37(S):150P. The Society of Nuclear Medicine 43rd Annual Meeting. Denver, Colorado, June 3 - 6, 1996.
54. Lai J, Baranowska-Kortylewicz J, Hoffman D, Dalrymple GV. Liver-specific agents for magnetic resonance imaging and scintigraphy. European J Nucl Med. 1995; 22:931. European Association of Nuclear Medicine Congress 1995. Brussels, Belgium, 26-30 August, 1995.
55. Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, Holdeman KP, Sharp G, Schneiderman MH, Clausen S, Hoffman D, Lai J, Schneiderman S. On the safety of 5-[^{125}I]iodo-2'-deoxyuridine in clinical applications. Book of Abstracts p. 27. Third International Symposium on Biophysical Aspects of Auger Processes. University of Lund, Sweden, August 24-25, 1995.

56. Kassis AI, Sahu SK, Wen PYC, Foulon C, Baranowska-Kortylewicz J, Van den Abbeele AD, Black PM, Adelstein SJ. 5-[^{125}I]Iodo-2'-deoxyuridine in radiotherapy of solid tumors in rats. Book of Abstracts p. 28. Third International Symposium on Biophysical Aspects of Auger Processes. University of Lund, Sweden, August 24-25, 1995.
57. Clausen S, Harrison K, Holdeman K, Dalrymple G, Baranowska-Kortylewicz J. Management of domestic swine during radioiodinated iododeoxyuridine instillation. 30th Annual Regional American Association of Laboratory Animal Science Meeting, St. Louis, MO April 6-8, 1995.
58. Mariani G, DiSacco S, Bonini R, Buralli S, Bonora D, Ricci S, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI, Falcone A. Tumor uptake of 5-[^{123}I]iodo-2'-deoxyuridine infused intra-arterially is biochemically modulated by 5-fluorouracil and folic acid. Book of Abstracts p. 29. Third International Symposium on Biophysical Aspects of Auger Processes. University of Lund, Sweden, August 24-25, 1995.
59. Baranowska-Kortylewicz J, Kortylewicz ZP, Hoffman D, Winoto A, Lai J, Dalrymple GV. Target-selective prodrugs of 5-radioiodo-2'-deoxyuridine. Book of Abstracts p. 42. Third International Symposium on Biophysical Aspects of Auger Processes. University of Lund, Sweden, August 24-25, 1995.
60. Holdeman K, Chiou R, Cohen S, Harrison K, Baranowska-Kortylewicz J, Schneiderman M, Sharp JG, Taylor R, Dalrymple G. Radioiodinated iododeoxyuridine (IUdR) for the identification and therapy of residual bladder cancer. Int J Radiat Biol. 1995; 68:354.
61. Collecchi P, Baldassarri S, DiSacco S, DiLuca L, Buralli S, Fontanini G, Gakis J, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI, Mariani G. Intra-tumor distribution of tumor uptake of 5-[^{125}I]iodo-2'-deoxyuridine after bladder instillation and mitotic activity in patients with bladder cancer. Book of Abstracts p. 44. Third International Symposium on Biophysical Aspects of Auger Processes. University of Lund, Sweden, August 24-25, 1995.
62. Mariani G, Collecchi P, Baldassarri S, DiSacco S, DiLuca L, Buralli S, Fontanini G, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. Patterns of tumor uptake of 5-[^{125}I]iodo-2'-deoxyuridine instilled intraluminally and of mitotic activity in patients with bladder cancer. Eur J Nucl Med. 1995; 22:830. European Association of Nuclear Medicine Congress, Aug. 26 - 30, 1995, Brussels, Belgium.
63. Mariani G, DiSacco S, Bonini R, Di Luca L, Buralli S, Ricci S, Baranowska-Kortylewicz J, Bonora D, Adelstein SJ, Kassis AI, Falcone A. Biochemical modulation by 5-fluorouracil and folic acid of tumor uptake of 5-[^{123}I]iodo-2'-deoxyuridine infused intra-arterially. Eur J Nucl Med. 1995; 22:830. European Association of Nuclear Medicine Congress, Aug. 26 - 30, 1995, Brussels, Belgium.
64. Tempero M, Leichner P, Harrison K, Baranowska-Kortylewicz J, Dalrymple G, Augustine S, Colcher D. The emerging role of radiolabeled antibodies in cancer. Conference on Innovative Therapies in Cancer Treatment. Ravena, Italy, Nov. 25-26, 1995.
65. Harrison K, Bierman P, Leichner P, Baranowska-Kortylewicz J, Quadri S, Holdeman K, Augustine S, Tempero M, Colcher D, Lai J, Helseth L, Schmidt B, Capadano M, Jacobson D, Kelly R, Witte R, Schneiderman M, Farnham M, Dalrymple GV. ^{90}Y Antiferritin for end-stage Hodgkin's disease. Ninth International Conference on Monoclonal Antibody Immunoconjugates for Cancer; San Diego, March 3_5, 1994. In: Antibody, Immunoconjugates, and Radiopharmaceuticals, 1994, 7:92.
66. Dalrymple GV, Taylor RJ, Baranowska-Kortylewicz J, Schneiderman MH, Chiou RK, Harrison KA, Leichner PK, Cavanaugh DJ, Holdeman KP, Augustine SC, Gobar LS, DeYoung L, Jacobson DA, Henriksen JL, Jenn JA, Kelly R, Lai J, Schmidt B, Schneiderman GS, Wobig H, Witte RJ, Charlton DE, Mariani G, Cohen SM. The potential value of the Auger electron emitters $^{123/125}$IUdR in the management of bladder cancer. The Second Annual Genitourinary Oncology Conference. Malignant Diseases of the Urothelium. January 14-15, 1994, Houston, Texas.

67. Dalrymple GV, Schneiderman MH, Baranowska-Kortylewicz J, Leichner PK, Harrison KA, Holdeman KP, Witte RJ, Taylor RJ, Chiou RK, Cohen SM, Sharp JG, Augustine SC, Tempero MA, Colcher DM, Jacobson DA, Mariani G, Charlton DE. Auger electron emitters for cancer imaging and quantification prior to therapy. The 42nd Annual Meeting of the Radiation Research Society, Nashville, Tennessee, April 29-May 4, 1994.
68. Schneiderman MH, Schneiderman GS, Charlton DE, Baranowska-Kortylewicz J, Dalrymple GV, Lai J, Helseth LD. Survival of s-phase Chinese hamster ovary cells labeled with ^{125}IUdR or ^{123}IUdR. The 42nd Annual Meeting of the Radiation Research Society, Nashville, Tennessee, April 29-May 4, 1994.
69. Kassis AI, Sahu SK, Kortylewicz ZP, Baranowska-Kortylewicz J, Adelstein SJ. DNA Strand breaks in plasmid pBR322 following positional decay of I-125. J Nucl Med. 1994; 35:79P. The 41st Annual Meeting of the Society of Nuclear Medicine, Orlando, Florida, June 8-11, 1994.
70. Mariani G, Di Sacco S, Volterrani D, Mateucci F, Baranowska-Kortylewicz J, Di Stefano R, Ricci S, Bellina CR, Di Luca L, Buralli S, Falcone A, Salvadori PA, Mosca F, Adelstein SJ, Kassis AI. Intra-arterial infusion of 5-[^{123}I]iodo-2'-deoxyuridine in patients with inoperable liver metastases from colorectal cancer. The 42nd Annual Meeting of the Radiation Research Society, Nashville, Tennessee, April 29-May 4, 1994.
71. Makrigiorgos GM, Folkard M, Bump E, Huang C, Baranowska-Kortylewicz J, Sahu SK, Michael BD, Kassis AI. Microdistribution and localization of hydroxyl radical within histone-DNA complexes using a molecular fluorescent detector. The 42nd Annual Meeting of the Radiation Research Society, Nashville, Tennessee, April 29-May 4, 1994.
72. Kassis AI, Sahu SK, Makrigiorgos GM, Baranowska-Kortylewicz J, Adelstein SJ. The effects of indium-111 decay on pBR322 DNA. J Nucl Med. 1994; 35:162P. The 41st Annual Meeting of the Society of Nuclear Medicine, Orlando, Florida, June 8-11, 1994.
73. Harrison K, Dalrymple GV, Baranowska-Kortylewicz J, Schneiderman MH, Holdeman K, Leichner P, Augustine SC, Jacobson D. Bladder cancer ^{123}IUdR imaging in preparation for ^{125}IUdR therapy. J Nucl Med. 1994; 35:144P. The 41st Annual Meeting of the Society of Nuclear Medicine, Orlando, Florida, June 8-11, 1994.
74. Mariani G, Di Sacco S, Volterrani D, Matteucci F, Baranowska-Kortylewicz J, Di Stefano R, Ricci S, Bellina CR, Di Luca L, Buralli S, Falcone A, Salvadori PA, Mosca F, Adelstein SJ, Kassis AI. Infusion of 5-[^{123}I]iodo-2'-deoxyuridine infused into the hepatic artery of patients with liver metastases from colorectal cancer. J Nucl Med. 1994; 35:144P The 41st Annual Meeting of the Society of Nuclear Medicine, Orlando, Florida, June 8-11, 1994.
75. Holdeman K, Dalrymple G, Taylor R, Cohen S, Schneiderman M, Baranowska-Kortylewicz J, Sharp J, Chiou R, Harrison K, Leichner P, Augustine S, Jacobson D, Helseth L, Clausen S, Mariani G, Charlton D. ^{125}IUdR Auger electron therapy: Preliminary bioeffects studies in a swine model. 1994 ASTRO Meeting. American Society for Therapeutic Radiology and Oncology, Oct. 3-6, 1994.
76. Sahu SK, Kortylewicz ZP, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. DNA strand breaks in plasmid pBR322 following positional decay of 125I. The 41st Annual Meeting of the Radiation Research Society, Dallas, Texas, March 20-25, 1993.
77. Makrigiorgos GM, Bump E, Baranowska-Kortylewicz J, Sahu SK, Kassis AI. Fluorescent detection of hydroxyl radical within angstroms of DNA, histones, nucleohistones and chromatin sites. The 41st Annual Meeting of the Radiation Research Society, Dallas, Texas, March 20-25, 1993.
78. Gongopadhyay A, Saravis C, Van den Abbeele AD, Baranowska-Kortylewicz J, Kassis AI. Semi-preparative isoelectrophoresis of DTPA-conjugated antibody leads to isolation of antibody isoforms with different immunoreactivities. J Nucl Med. 1993; 34:247P. The 40th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada, June 8-11, 1993.

79. Kassis AI, Van den Abbeele AD, Wen PYC, Baranowska-Kortylewicz J, Metz KR, Cook C, Sahu SK, White J, Barclay PD, Black PM, Adelstein SJ. 5-[I-125]Iodo-2'-deoxyuridine in the radiotherapy of solid brain tumors in rats. J Nucl Med. 1993; 34:241P. The 40th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada, June 8-11, 1993.
80. Van den Abbeele AD, Barclay PD, Tutrone RF, Goldstein DS, Baranowska-Kortylewicz J, Ritchie JP, Adelstein SJ, Kassis AI. Diagnostic and therapeutic implications of radioiodinated IUdR uptake in exfoliated cells obtained from patients with bladder cancer. J Nucl Med. 1993; 34:221P. The 40th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada, June 8-11, 1993.
81. Van den Abbeele AD, Tutrone RF, Goldstein DS, Berman RB, Barclay PD, Baranowska-Kortylewicz J, Lage AL, Richie JP, Adelstein SJ, Kassis AI. Radioiodinated 5-iodo-2'-deoxyuridine in bladder cancer: Diagnostic and potential therapeutic applications. J Nucl Med. 1993; 34:123P. The 40th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada, June 8-11, 1993.
82. Baranowska-Kortylewicz J, Bierman PJ, Quadri SM, Harrison KA, Lai J, Leichner PK, Holdeman KP, Augustine SC, Schneiderman MH, Tempero MA, Colcher DM, Jacobson DA, Dalrymple GV. Pharmacokinetics and stability of polyclonal antiferritin antibodies (RTAF) in patients with advanced Hodgkin's disease. Eur J Nucl Med. 1993; 20:986. European Association of Nuclear Medicine Congress 1993. Lausanne, Switzerland, October 10-14, 1993.
83. Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht SJ, Adelstein SJ, Kassis AI. A three-step procedure for the targetting of tumours using avidin-biotin system. The Australia/New Zealand Society of Nuclear Medicine Scientific Meeting, Canberra, Australia, May 16-19, 1993.
84. Baranowska-Kortylewicz J, Schneiderman MH, Chiou RK, Harrison KA, Leichner PK, Cavanaugh D, Holdeman KP, Augustine S, Gobar LS, DeYoung L, Gilmore P, Jacobson D, Henriksen JL, Jenn J, Kelly R, Schmidt B, Schneiderman S, Wobig H, Witte R, Mariani G, Cohen SM, Taylor RJ, Dalrymple GV. Diagnostic studies of bladder cancer with 5-[^{125}I]iodo-2'-deoxyuridine. European Association of Nuclear Medicine Congress 1993. Lausanne, Switzerland, October 10-14, 1993.
85. Smith SV, Lambrecht RM, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Adelstein SJ, Kassis AI. A three-step procedure for the targetting of tumours using the avidin-biotin system. Aust N Z J Med. 1994; 24:511.
86. Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Kassis AI. A three-step strategy using the avidin-biotin system for radioimaging tumours. The 10th International Symposium on Radiopharmaceutical Chemistry. Kyoto, Japan, October 25-28, 1993.
87. Mariani G, Di Sacco S, Matteucci F, Volterrani D, Baranowska-Kortylewicz J, Di Stefano R, Ricci S, Bellina CR, Troiani R, Di Luca L, Falcone A, Salvadori PA, Conte PF, Sicari A, Mosca F, Adelstein SJ, Kassis AI. Tumor targeting by intra-arterial infusion of 5-[I-123]iodo-2'-deoxyuridine in patients with liver metastases from colon cancer. European J Nucl Med. 1993; 20:886. European Association of Nuclear Medicine Congress 1993. Lausanne, Switzerland, October 10-14, 1993.
88. Mariani G, Vitek F, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Di Sacco S, Meucci G, Salvadori PA, Adelstein SJ, Kassis AI. Pharmacokinetics in humans of 5-[I-125]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer. Eur J Nucl Med. 1993; 20:991. European Association of Nuclear Medicine Congress 1993. Lausanne, Switzerland, October 10-14, 1993.
89. Mariani G, Di Sacco S, Matteucci F, Volterrani D, Baranowska-Kortylewicz J, Ricci S, Di Stefano R, Troiani R, Di Luca L, Falcone A, Bellina CR, Salvadori PA, Conte PF, Sicari A, Mosca F, Adelstein SJ, Kassis AI. Intra-arterial infusion of 5-[123I]iodo-2'-deoxyuridine in patients with liver

metastases from colon cancer. J Nucl Biol Med. 1993; 37:157-158. Eight International Symposium on Radiopharmacology. Ghent, Belgium, September 5-9, 1993.

90. Sahu SK, Kassis AI, Baranowska-Kortylewicz J, Makrigiorgos GM, Adelstein SJ. DNA strand breaks in plasmid pBR 322 following ^{111}In decay. The 40th Annual Meeting of The Radiation Research Society, Salt Lake City, Utah, March 14-18, 1992.
91. Mariani G, Cei A, Giuliani L ,Baranowska-Kortylewicz J., Collecchi G, Van den Abbeele AD, Di Luca L, Di Stefano R, Bevilacqua G, Salvadori PA, Adelstein SJ, Mosca F, Kassis AI. Intratumoral injection of 5-[^{125}I]iodo-2'-deoxyuridine (^{125}IUdR) in patients with gastrointestinal or breast cancer. The 40th Annual Meeting of the Radiation Research Society, Salt Lake City, Utah, March 14-18, 1992. Rad Res. 1992; 38:A422-A422.
92. Makrigiorgos G, Baranowska-Kortylewicz J, Bump E, Berman RM, Sahu S, Kassis AI. Radiation induced fluorescence of protein and DNA solutions: An approach to molecular dosimetry. The 40th Annual Meeting of the Radiation Society, Salt Lake City, Utah, March 14-18, 1992.
93. Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI. 5-[$^{123/125}$I]Iodo-2'-deoxyuridine [*IUdR] as diagnostic and potential therapeutic agents for bladder cancer. The 40th Annual Meeting of the Radiation Society, Salt Lake City, Utah, March 14-18, 1992.
94. Mariani G, Baranowska-Kortylewicz J, Di Stefano R, Giuliani L, Di Luca L, Van den Abbeele AD, Adelstein SJ, Kassis AI. Metabolism of 5-[^{125}I]iodo-2'-deoxyuridine injected intratumorally in patients with colon or breast cancers. European J Clin Invest. 1992; 22:A23.
95. Mariani G, Cei A, Giuliani L, Collecchi P, Baranowska-Kortylewicz J, Di Stefano R, Meucci G, Di Luca L, Van den Abbeele AD, Adelstein SJ, Kassis AI. Intratumoral injections of 5-[^{125}I]iodo-2'-deoxyuridine in patients with gastrointestinal or breast cancers. Clin Res. 1992; 40:422A.
96. Mariani G, Cei A, Baranowska-Kortylewicz J, Collecchi P, Di Stefano R, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Bevilacqua G, Adelstein SJ, Kassis AI. Tumor targeting potential of 5-[^{125}I]iodo-2'-deoxyuridine injected intratumorally in patients with gastrointestinal or breast cancers. Eur J Nucl Med. 1992; 19:705.
97. Mariani G, Cei A, Collecchi P, Van den Abbeele AD, Baranowska-Kortylewicz J, Bevilacqua G, Guadagni A, Di Luca L, Di Stefano R, Salvadori PA, Adelstein SJ, Mosca F, Kassis AI. Intratumoral injections of 5-^{125}I-iodo-2'-deoxyuridine in patients with colon cancer. In: Book of Abstracts of the 7th International Symposium on Radiopharmacology, Boston, MA June 3-6, 1991.
98. Kortylewicz ZP, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. Synthesis of substituted acridines and their interaction with isolated calf thymus DNA and cellular DNA of V79 cells in vitro. In: Book of Abstracts of the 32nd National Organic Chemistry Symposium, Minneapolis, June 16-20, 1991.
99. Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. Sulfhydryl-selective photoaffinity, radioiodinating and fluorescent reagents for proteins. In: Book of Abstracts 32nd National Organic Chemistry Symposium, Minneapolis, June 16-20, 1991.
100. Kassis AI, Van den Abbeele AD, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LC, Black PM, Adelstein SJ. Therapeutic implications of 5-[^{123}I]Iodo-2'-deoxyuridine administered to rats with brain tumors. In: Proceedings of the 38th Annual Meeting of the Radiation Research Society, New Orleans, April 7-12, 1990, p. 134.
101. Van den Abbeele AD, Wen PYC, Makrigiorgos GM, Baranowska-Kortylewicz J, Lampson LA, Black PM, Adelstein SJ, Kassis AI. Autoradiographic validation of 5-[$^{123/125}$I]iodo-2'-deoxyuridine as a diagnostic and potential therapeutic agent for brain tumors. In: Proceedings of the 38th Annual Meeting of the Radiation Research Society, New Orleans, April 7-12, 1990, p. 133.

102. Baranowska-Kortylewicz J, Adelstein SJ, Mariani G, Kassis AI. 5-Iodo-2'-eoxyuridine - protein conjugates. 2. Synthesis and in vitro and in vivo behavior of ^{125}IUdR - protein conjugates. In: Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, March 30-April 1, 1989, p. 93.
103. Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. Covalent attachment of 4-bromo-6,7-dimethoxy-2-oxo-2H-benzopyran and its radioiodinated derivative to sulfhydryl groups of protein. In: Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, March 30-April 1, 1989, p.119.
104. Baranowska-Kortylewicz J, Kassis AI. Radioimmunoassay for antibodies recognizing antigenic gangliosides. In: Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, March 30 - April 1, 1989, p. 216.
105. Kassis AI, Makrigiorgos M, Baranowska-Kortylewicz J, McElvany KD, Sastry KSR, Adelstein SJ. Radiotoxicity of ^{123}IUdR in V79 cells: A comparison with ^{125}IUdR. In: Proceedings of the 37th Annual Meeting of the Radiation Research Society, March 18-23, 1989, p. 97.
106. Makrigiorgos M, Kassis AI, Ito S, Baranowska-Kortylewicz J, Vinter D, Van den Abbeele AD, Adelstein SJ. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: Experimental evidence and dosimetric implications. In: Proceedings of the 37th Annual Meeting of the Radiation Research Society, March 18-23, 1989, p.127.
107. Baranowska-Kortylewicz J, Adelstein SJ, Berman RM, Kassis AI. 5-[^{123}I]Iodo- 2'-deoxyuridine in therapy of an early ascites tumor. J Nucl Med. 1989; 30:882. 35th Annual Meeting of the Society of Nuclear Medicine, St. Louis, June 14-17, 1989.
108. Baranowska-Kortylewicz J, Kassis AI. Determination of the immunoreactive fraction of antibodies recognizing antigenic gangliosides. J Nucl Med. 1989; 30:919. 35th Annual Meeting of the Society of Nuclear Medicine, St. Louis, June 14-17, 1989.
109. Baranowska-Kortylewicz J, Smith WT. Synthesis of 3,9-disubstituted purines and their platinum(II) complexes. In: Book of Abstracts of the 31st National Organic Symposium of the American Chemical Society, Ithaca, June 18-22, 1989, p. A3.
110. Makrigiorgos GM, Ito S, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: Experimental evidence and dosimetric implications. J Nucl Med. 1989; 30:823. 35th Annual Meeting of the Society of Nuclear Medicine, St. Louis, June 14-17, 1989.
111. Makrigiorgos GM, Baranowska-Kortylewicz J, Van den Abbeele AG, Ito S, Vinter SJ, Adelstein SJ, Kassis AI. Microscopic spatial inhomogeneity in mammalian tissues: Dosimetry at the cellular level and comparison with conventional dosimetry. In: Proceedings of the Tenth European Microdosimetry Symposium, Rome, Italy, May 22-26, 1989, p. 91.
112. Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. 5-Iodo-2'-deoxyuridine-protein conjugates. In: Proceedings of the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, Feb. 4-6, 1988, p.112.
113. Baranowska-Kortylewicz J, Smith WT. New substituted purines and uracils for platinum(II) complexes. In: Book of Abstracts of the 33rd Southeastern American Chemical Society Regional Meeting, Lexington, Nov. 4-6, 1981, p. 45.

BOOKS AND CHAPTERS

1. Baranowska-Kortylewicz J, Dalrymple GV, Quadri SA, Harrison KA. Radiolabeling of Antibodies for Diagnosis and Therapy. In Antibody Engineering Protocols. Humana Press, Totowa, New Jersey, 1995 (Paul S., Editor), pp. 423-441.

2. Mariani G, Giuliani L, Baranowska-Kortylewicz J, Collecchi P, Meucci G, Di Luca L, Viacava P, Van den Abbeele AD, Bevilacqua G, Salvadori PA, Adelstein SJ, Kassis AI. Intratumoral injection of 5-[^{125}I]iodo-2'-deoxyuridine in patients with breast cancer. In: Hofer R, Bergamn H, Sinzinger H, eds. Radioactive Isotopes in Clinical Medicine and Research. Stuttgart: Schattauer Verlag, 1992, pp 188-193.
3. Van den Abbeele A, Baranowska-Kortylewicz J, Adelstein SJ, Carvalho PA, Tutrone RF, Richie JP, Wen PYC, Black PMcL, Mariani G, Kassis AI. Diagnostic and therapeutic applications of Auger-electron-emitting 5-[^{123,125}I]iodo-2'-deoxyuridine in cancer. In: AAMP Monograph, Amherst, MA 1991.
4. Baranowska J., Fort A.W., Davis B.H.: Amine distribution and average base strengths of amine mixtures from SCR_1 samples, 82/076. Lexington, IMMR Books 1982.
5. Van den Abbeele AD, Baranowska-Kortylewicz J, Adelstein SJ, Carvalho PA, Tutrone RF, Riche JP, Wen PYC, Black PMcL, Mariani G Kassis AI. Diagnostic and therapeutic application of Auger-electrons-emitting 5[123/125]iodo-2-deoxyuridine in cancer. In Howell RW, Narra VR, Sastry KSR, Rao DV, eds. Biophysical aspect of Auger processes, AAPM Symposium Proceeding number 8. 1992; 372-395.

TEACHING ACTIVITIES AT UNMC

1998 - 2019

UNMC Undergraduate Summer Research Program; https://www.unmc.edu/studentservices/rse/enrichment/undergraduate-enrichment/surp/departments.html.

2016 - 2019

MITS 438/638N Advanced Radiation Biology, UNMC Department of Medical Imaging & Therapeutic Sciences, College of Allied Health Professions

1993 - 2016

RSTE 438N Advanced Radiation Biology, University of Nebraska Medical Center, School of Allied Health Professions, Omaha, Nebraska